MarketCapExport financials
Fulgent Genetics (FLGT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Fulgent Genetics Financial Ratios 2025-2011 | FLGT
Brief overview of Fulgent Genetics's multiples and efficiency
The review covers five available annual periods spanning 2016 to 2022.
Key multiples at the end of the period are P/E 6.92x (median 6.92x), EV/EBITDA 4.88x (median 8.07x), P/S 1.63x (median 1.65x). The combined ratio level is close to the company's five-year norm at a -0.9% deviation. No clear premium or discount is visible.
The 1/P/E calculation produces a 14.4% earnings yield. It does not capture future growth or capital structure.
The latest available business-quality ratios are ROE -5.4%, ROA -5%, ROCE -8.2%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
On PEG (0.21x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
The time from paying for inputs to receiving cash rose from 19.6 days to 51.8 days. Cash turnover slowed.
What the ratios show
Fulgent Genetics's market valuation is near its own historical norm, while quality ratios provide no extreme signal.
Annual Financial Ratios Fulgent Genetics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.7 | -10.9 | -4.2 | 6.9 | 3.6 | 10.7 | -615.0 | -12.3 | -33.9 | -42.0 | - | - | - | - | - | |
P/S |
1.6 | 1.6 | 2.4 | 1.6 | 1.8 | 5.4 | 7.8 | 3.2 | 4.5 | 12.3 | - | - | - | - | - |
EPS |
-2.0 | -1.4 | -5.6 | 4.8 | 17.2 | 9.4 | -0.0 | -0.3 | -0.1 | - | - | - | - | - | - |
EV (Enterprise Value) |
583 M | 502 M | 705 M | 1.03 B | 1.78 B | 2.34 B | 247 M | 65.2 M | 81.7 M | 220 M | 686 K | 436 K | - | - | - |
EBITDA per Share |
-2.18 | -1.62 | -5.69 | 7.02 | 23.4 | 12.9 | 0.0897 | -0.162 | -0.0989 | 0.118 | - | - | - | - | - |
EV/EBITDA |
-8.7 | -10.3 | -4.2 | 4.9 | 2.6 | 8.0 | 143.4 | -21.5 | -44.8 | 103.8 | - | - | - | - | - |
PEG |
0.21 | -0.0 | -0.0 | 0.0 | 0.0 | 0.0 | -6.68 | 0.19 | -0.67 | -0.87 | - | - | - | - | - |
P/B |
0.5 | 0.4 | 0.6 | 0.8 | 1.6 | 4.0 | 3.1 | 1.4 | 1.6 | 4.1 | - | - | - | - | - |
P/CF |
-5.2 | 22.2 | 26.0 | 3.9 | 3.4 | 16.3 | 60.2 | -19.7 | -21.2 | 364.1 | - | - | - | - | - |
ROE % |
-5.44 | -3.77 | -14.77 | 11.32 | 43.79 | 37.64 | -0.50 | -10.96 | -4.63 | -9.81 | - | - | - | - | - |
ROA % |
-4.99 | -3.50 | -13.59 | 10.35 | 39.68 | 30.60 | -0.46 | -10.40 | -4.39 | -9.21 | - | - | - | - | - |
ROCE % |
-8.03 | -6.42 | -16.78 | 13.79 | 57.96 | 50.87 | -0.50 | -9.91 | -6.43 | 1.68 | - | - | - | - | - |
Current Ratio |
11.4 | 13.4 | 12.1 | 11.9 | 11.3 | 5.3 | 10.0 | 14.4 | 11.0 | 7.9 | - | - | - | - | - |
DSO |
87.0 | 77.4 | 65.6 | 56.5 | 59.3 | 82.4 | 80.8 | 106.6 | 83.3 | 91.3 | - | - | - | - | - |
DIO |
- | - | - | - | - | - | 7.2 | 10.7 | 9.9 | 17.5 | - | - | - | - | - |
DPO |
35.2 | 34.9 | 38.0 | 31.6 | 39.8 | 57.0 | 40.9 | 44.8 | 89.2 | 149.6 | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | 87.9 | 117.4 | 93.2 | 108.8 | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | 47.0 | 72.6 | 4.0 | -40.8 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Fulgent Genetics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.48 | -1.05 | -0.8 | -0.76 | -0.21 | -0.62 | -0.37 | -0.18999999999999995 | -0.48 | -0.29 | -0.45 | -4.3 | -0.44 | -0.38 | -0.52 | -0.8 | 0.06 | 0.38 | 5.09 | 3.48 | 4.13 | 2.74 | 6.96 | 6.55 | 2.11 | 0.15 | -0.09 | -0.01 | 0.08 | 0.02 | -0.1 | -0.11 | -0.03 | -0.06 | -0.11 | -0.09 | -0.06 | - | 0.01 | 0.05 | -0.44 | -5.49 | -0.02 | -0.61 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.73 | -1.2 | -1.06 | -496 | -0.43 | -0.58 | -0.58 | -101 | -0.5 | -0.56 | -0.67 | 29.8 K | 0.07 | -0.6 | -0.77 | 217 | 0.08 | 0.64 | 6.71 | 812 | 5.39 | 3.47 | 9.32 | 252 | 2.91 | 0.15 | -0.06 | 0.4 | 0.11 | 0.04 | -0.07 | -0.03 | -0.02 | -0.02 | -0.09 | -0.12 | -0.06 | 0.01 | 0.04 | 0.07 | -0.03 | 97.9 | -0.03 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-8.79 | -8.05 | -6.79 | -5.44 | -3.84 | -4.54 | -3.61 | -3.78 | -14.56 | -14.31 | -14.43 | -14.44 | -5.03 | -3.89 | -2.12 | 10.78 | 21.57 | 33.17 | 40.94 | 54.28 | 74.60 | 87.84 | 83.01 | 55.57 | 26.00 | 3.74 | 0.57 | -0.85 | -4.50 | -8.32 | -11.01 | -10.80 | -9.78 | -13.28 | -11.28 | -7.25 | -2.76 | -0.16 | -8.36 | -9.89 | -153.96 | -129.00 | -1.11 | -142.58 | 22.93 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-8.01 | -7.33 | -6.20 | -5.01 | -3.56 | -4.21 | -3.33 | -3.47 | -13.36 | -13.14 | -13.26 | -13.28 | -4.65 | -3.58 | 7.72 | 16.94 | 28.83 | 28.73 | 36.32 | 45.93 | 61.56 | 70.27 | 66.15 | 43.87 | 19.80 | 3.33 | 0.45 | -0.78 | -4.26 | -7.74 | -10.27 | -10.28 | -9.32 | -12.62 | -10.72 | -6.87 | -2.63 | -0.14 | -7.84 | -9.28 | -136.49 | -114.35 | -1.04 | -125.81 | 20.23 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-12.24 | -11.35 | -9.55 | -8.04 | -6.23 | -6.36 | -6.25 | -6.40 | -18.00 | -16.51 | -16.41 | -16.44 | -6.25 | -6.24 | -3.73 | 13.44 | 29.11 | 44.15 | 53.82 | 71.83 | 98.58 | 117.03 | 109.33 | 73.78 | 33.69 | 2.83 | 0.43 | -0.75 | -2.28 | -6.54 | -9.05 | -9.71 | -11.52 | -12.65 | -10.96 | -6.42 | -0.30 | 1.16 | 3.21 | 1.68 | -143.34 | -119.13 | -1.13 | -142.71 | 22.93 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
11.4 | 11.7 | 10.3 | 11.4 | 12.9 | 13.6 | 14.5 | 13.4 | 12.5 | 11.9 | 11.9 | 12.1 | 14.1 | 14.8 | 12.8 | 11.9 | 11.3 | - | 9.6 | 11.3 | 7.5 | 8.1 | 5.1 | 5.3 | 4.1 | 10.8 | 11.2 | 14.8 | 9.2 | 10.7 | 9.8 | 19.6 | 24.2 | 19.6 | 23.0 | 19.0 | 19.0 | 19.1 | 19.0 | 16.3 | 16.3 | 16.3 | 16.3 | 8.5 | 8.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
64.3 | 71.7 | 98.8 | 85.4 | 80.5 | 82.9 | 87.3 | 75.6 | 72.4 | 69.8 | 73.0 | 65.0 | 45.3 | 52.7 | 66.4 | 105.7 | 45.0 | 58.3 | 42.6 | 47.1 | 53.9 | 108.4 | 50.8 | 42.5 | 46.9 | 53.5 | 76.1 | 64.5 | 47.8 | 54.7 | 89.3 | 96.7 | 97.5 | 92.2 | 88.0 | 85.4 | 83.0 | 80.5 | 72.0 | 68.0 | 79.5 | 100.3 | 86.0 | 66.6 | 33.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
1.1 | 1.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
25.4 | 28.0 | 36.6 | 33.0 | 34.7 | 35.8 | 37.0 | 39.2 | 40.2 | 40.5 | 37.6 | 31.4 | 37.0 | 41.2 | 43.5 | 31.3 | 11.1 | 18.0 | 25.9 | 33.3 | 41.6 | 41.0 | 27.1 | 39.8 | 38.8 | 38.4 | 49.9 | 46.8 | 39.0 | 33.2 | 42.6 | 38.5 | 40.8 | 47.7 | 56.5 | 74.9 | 78.6 | 94.9 | 118.9 | 135.0 | 117.3 | 178.2 | 107.4 | 10.5 | 15.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
65.4 | 72.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 58.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100.5 | - | - | 81.2 | - | 72.0 | - | 79.5 | 100.3 | 86.0 | 66.6 | 33.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
40.1 | 44.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.4 | - | - | -2.9 | - | -47.0 | - | -37.9 | -78.0 | -21.4 | 56.1 | 17.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Fulgent Genetics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B |  USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |
 |
Interpace Biosciences
IDXG
|
$ 7.0 | -13.43 % | $ 31 M | USA |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 204.62 | -1.43 % | $ 16 B |  Irlanda |
 |
Co-Diagnostics
CODX
|
$ 0.29 | -9.5 % | $ 386 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.19 | 6.46 % | $ 135 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 2.37 | 15.05 % | $ 9.44 M | Israel |
 |
Myriad Genetics
MYGN
|
$ 5.66 | -1.39 % | $ 524 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 4.78 | -1.24 % | $ 3.76 M | USA |
 |
QIAGEN N.V.
QGEN
|
$ 50.52 | -0.07 % | $ 11 B |  Niderland |
 |
NeoGenomics
NEO
|
$ 16.97 | -3.58 % | $ 2.17 B | USA |
 |
OPKO Health
OPK
|
$ 1.71 | 0.58 % | $ 1.28 B | USA |